Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983914 | 0.79 | LMNA (0.39) | LMNACYP2C19CA12CA1CA2 | |
| SCHEMBL1877202 | 0.77 | TP53 (0.35) | TP53CA12CA1CA2MMP1 | |
| SCHEMBL2978531 | 0.77 | SMN1; SMN2 (0.41) | LMNACYP2C19CA12CA1CA2 | |
| SCHEMBL7620707 | 0.77 | LMNA (0.38) | LMNACYP2C19CA12CA1CA2 | |
| SCHEMBL6473670 | 0.77 | LMNA (0.38) | LMNACYP2C19CA12CA1CA2 | |
| SCHEMBL24801628 | 0.77 | TP53 (0.35) | TP53 | |
| SCHEMBL15970677 | 0.77 | CTSA (0.40) | LMNACYP2C19TP53TDP1 | |
| SCHEMBL2991395 | 0.75 | TP53 (0.33) | TP53CA12CA1CA2MMP1 | |
| SCHEMBL8644884 | 0.74 | LMNA (0.44) | LMNACYP2C19TP53TDP1SLC1A3 | |
| SCHEMBL11268072 | 0.73 | CYP2C19 (0.32) | LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882030-B1 | NON-AQUEOUS ELECTROLYTE AND ENERGY STORAGE DEVICE USING THE SAME | UBE INDUSTRIES (JP) | 2017-06-21 | — | — | EP | claimed |
| CN-115197160-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-10-18 | — | — | CN | disclosed |
| CN-107108506-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-21 | — | — | CN | disclosed |
| CN-109415384-B | Fused heterocyclic compound | 武田药品工业株式会社 | 2022-01-11 | — | — | CN | disclosed |
| CN-107848971-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-03-26 | — | — | CN | disclosed |
| CN-108026088-B | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| CN-108431004-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| WO-2020069055-A1 | TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2018029699-A1 | SOLID STATE FORMS OF (2E)-N-HYDROXY-3-[3-(PHENYLSULFAMOYL)PHENYL]PROP-2-ENAMIDE AND PROCESS FOR PREPARATION THEREOF | MSN RESEARCH & DEVELOPMENT CENTER (IN) | 2018-02-15 | — | — | WO | disclosed |
| EP-2287157-A1 | METHOD FOR OBTAINING CINATRINS C3 AND C1 | Consejo Superior de Investigaciones Cientificas (ES) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010026214-A1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-7579487-B2 | Process for making N-sulfonated-amino acid derivatives | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | MERCK SHARP & DOHME CORP. | 2007-09-20 | — | — | US | disclosed |
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| US-4591651-A | Process for directly converting an aldehyde into an ethylene ester | AGRIFURANE S.A. (FR) | 1986-05-27 | — | — | US | disclosed |
| US-4338458-A | Cyclopentane derivatives useful as perfuming agents | FIRMENICH SA (CH) | 1982-07-06 | — | — | US | disclosed |
| EP-0000833-B1 | DERIVATIVES OF PHOSPHONOACYL PROLINES AND THEIR PHARMACEUTICAL USE | E.R. Squibb & Sons, Inc. (US) | 1981-09-02 | — | — | EP | disclosed |
| US-4151172-A | Phosphonoacyl prolines and related compounds | E. R. SQUIBB & SONS, INC. (US) | 1979-04-24 | — | — | US | disclosed |
| EP-0000833-A1 | Derivatives of phosphonoacyl prolines and their pharmaceutical use | E.R. Squibb & Sons, Inc. (US) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | GPR119, ACOX1, ALK | LMNA 1867/4885CYP2C19 744/4885TP53 4164/4885 |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | ANTXR2, STS, ASNS | LMNA 1930/4885CYP2C19 2175/4885TP53 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.